Partner with MoleculeDx to offer your at-risk patients best-in-class HCC surveillance without adding clinical burden.
Our provider program integrates seamlessly with existing clinical workflows. Order tests, track results, and receive actionable alerts — all within your existing systems.
Order MoleculeDx tests directly from your EHR via HL7/FHIR integration or our lightweight web portal. CPT coding and billing support included.
Results are delivered directly to your preferred EHR system within 24 hours. Flags and abnormal results trigger real-time provider alerts via your preferred channel.
We handle all patient communication, scheduling, and home visit logistics. Your team only needs to order the test — we manage the rest.
Track screening compliance across your entire at-risk patient panel. Identify gaps, set reminders, and report on program performance — all in one dashboard.
As our flagship clinical partner, UPMC has developed a full integration protocol for the MoleculeDx test. We work with UPMC’s oncology team on all positive result referrals.
Our billing team handles prior authorization, insurance verification, and appeals for denied claims. We maximize reimbursement so your patients face minimal out-of-pocket cost.
UPMC physicians can order the test via the UPMC Epic integration, or patients can self-refer by walking in to any UPMC facility and requesting the MoleculeDx liver cancer screen.
At UPMC sites with phlebotomy services, the blood draw is performed on-site. For patients who prefer at-home collection, Portamedic or Travalab is dispatched to their address.
Results are returned within 24 hours directly to the patient’s UPMC Epic record. Abnormal results trigger automatic alerts to the ordering physician and UPMC Hepatology.
Ready to set up MoleculeDx in your practice or health system? Our clinical partnerships team can have you onboarded in under a week.
You may benefit from regular liver cancer screening if you have one or more of these conditions.
The test screens for hepatocellular carcinoma (HCC) — the most common form of primary liver cancer. We analyze your blood for fusion gene biomarkers that are specific to early-stage liver cancer. These markers appear in the bloodstream significantly earlier than tumors become visible on ultrasound or CT scans.
First-in-class blood-based liver cancer early detection. Powered by Fusion-detect™ AI genomics technology.
© 2026 MoleculeDx Inc. All rights reserved.
This test is not a substitute for medical diagnosis. Consult your physician with all results.